Bookmark

Add to MyYahoo RSS

Alexion Pharmaceuticals News

News on Alexion Pharmaceuticals (Ticker: ALXN) continually updated from thousands of sources around the net.

21 hrs ago | AmericanBankingNews.com

Alexion Pharmaceuticals Receives Consensus Recommendation of...

Shares of Alexion Pharmaceuticals have received an average rating of "Buy" from the eighteen analysts that are covering the stock, StockRatingsNetwork reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

Wed Aug 20, 2014

AmericanBankingNews.com

Insider Selling: Alexion Pharmaceuticals CEO Leonard Bell Sells 70,000 Shares of Stock

Alexion Pharmaceuticals CEO Leonard Bell unloaded 70,000 shares of the stock on the open market in a transaction dated Friday, August 15th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

Mon Aug 18, 2014

AmericanBankingNews.com

Insider Selling: Alexion Pharmaceuticals CEO Unloads 70,000 Shares of Stock

Alexion Pharmaceuticals CEO Leonard Bell unloaded 70,000 shares of the company's stock in a transaction dated Friday, August 15th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

Pharmaceutical Online

Weekly FDA Enforcement Report For Drugs 8/13/14

The Food and Drug Administration has released its Drug product Enforcement Report for August 13, 2014.

Comment?

Related Topix: Food and Drug Administration, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Thu Aug 14, 2014

GuruFocus.com

Alexion CEO Receives Nearly $17 Million for Sale of Company Stock

The CEO of Alexion Pharmaceuticals Inc , Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Aug 13, 2014

AmericanBankingNews.com

Insider Selling: Alexion Pharmaceuticals CEO Sells 80,458 Shares of Stock

Alexion Pharmaceuticals CEO Leonard Bell sold 80,458 shares of the stock on the open market in a transaction that occurred on Tuesday, August 12th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

AmericanBankingNews.com

Insider Selling: Leonard Bell Unloads 105,000 Shares of Alexion Pharmaceuticals Stock

Alexion Pharmaceuticals CEO Leonard Bell sold 105,000 shares of the company's stock in a transaction dated Wednesday, August 13th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

Customer Interaction Solutions

Researchers to Present New Data on Asfotase Alfa in Pediatric...

Alexion Pharmaceuticals, Inc. today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia will be presented at the American Society for Bone and Mineral Research 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Food and Drug Administration

Tue Aug 05, 2014

AmericanBankingNews.com

Alexion Pharmaceuticals CFO Vikas Sinha Sells 1,525 Shares

Alexion Pharmaceuticals CFO Vikas Sinha sold 1,525 shares of the stock in a transaction that occurred on Monday, August 4th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

AmericanBankingNews.com

Alexion Pharmaceuticals EVP Sells $213,142 in Stock

Alexion Pharmaceuticals EVP David Hallal unloaded 1,349 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 4th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

BioResearch Online

EC Designates Orphan Status To Alexion's Soliris For MG

Alexion Pharmaceuticals reported that the European Commission has designated its drug Soliris orphan drug status for the treatment of rare disease Myasthenia Gravis .

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Myasthenia Gravis, Health

Fri Aug 01, 2014

BioSpace

Alexion Pharmaceuticals Inc. Release: European Commission Grants...

Alexion Pharmaceuticals today announced that the European Commission has granted orphan drug designation to SolirisA for the treatment of patients with Myasthenia Gravis , a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics, Myasthenia Gravis, Health

Mon Jul 28, 2014

Seeking Alpha

Alexion Looks Better After Q2 Earnings

Alexion reported earnings last week that failed to excite investors as the share price went down in the next two days.

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Fri Jul 25, 2014

AmericanBankingNews.com

Stifel Nicolaus Reiterates Buy Rating for Alexion Pharmaceuticals

's stock had its "buy" rating reiterated by investment analysts at Stifel Nicolaus in a note issued to investors on Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

The Hartford Courant

Alexion Profits Up 38% From A Year Earlier

Alexion Pharmaceuticals, the highly successful biotech company headquartered in Cheshire, grew profits by more than $70 million in the second quarter of 2014 compared with the same period a year earlier, as more patients start on Soliris, which is then needed for the rest of their lives.

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Cheshire, CT, New Haven, CT

Thu Jul 24, 2014

Forbes.com

Thursday Sector Laggards: Materials, Healthcare

The worst performing sector as of midday Thursday is the Materials sector, not showing much of a gain.

Comment?

Related Topix: Industrial Machines, Precision Castparts, Aerospace-Defense, Metals, Real Estate, Freeport, Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Investor's Business Daily

Celgene, Alexion Beat Estimates, But Biotechs Fall

Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector.

Comment?

Related Topix: Biotech, Celgene, Medicine, Healthcare Industry, Taligen Therapeutics

Seeking Alpha

Alexion Pharmaceuticals' (ALXN) CEO Leonard Bell on Q2 2014 Results - Earnings Call Transcript

Good morning, and welcome to the Alexion Pharmaceuticals, Incorporated Second Quarter 2014 Results Conference Call.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Marketing

BioSpace

Alexion Pharmaceuticals Inc. Release: European Medicines Agency...

Alexion Pharmaceuticals, Inc. today announced that the Marketing Authorization Application for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia , has been validated and granted accelerated assessment by the European Medicines Agency .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Marketing

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

The International Center for Dispute R... )--Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECU... Resumen: La Agencia Europea del Medicamento acepta la solicitud de autorizacin de marketing de Asfotasa Alfa como tratamiento ... (more)

Comment?

Related Topix: TapImmune, Marketing, Biotech, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••